Literature DB >> 2871102

Comparison of the solid phase enzyme receptor assay (SPERA) and the microbiological assay for teicoplanin.

L Cavenaghi, A Corti, G Cassani.   

Abstract

A solid phase enzyme receptor assay (SPERA) for teicoplanin has been developed and recently presented in a kit form. The assay relies on the competition between antibiotic present in the biological fluid and peroxidase labelled teicoplanin for albumin-epsilon-amino-caproyl-D-alanyl-D-alanine (BSA-epsilon-ACA-D-Ala-D-Ala), a synthetic analog of the biological receptor. The kit contains BSA-epsilon-ACA-D-Ala-D-Ala coated microplates together with all the necessary reagents. The limit of detection of the SPERA is 0.5 mg 1(-1). The microbiological assay for teicoplanin uses Bacillus subtilis ATCC 6633 as test organism and a high salt medium to ensure a low limit of detection of 0.05 mg 1(-1). The previously established correlation between the two methods has been confirmed using the kits on 280 serum and 216 urine samples with concentrations up to 500 mg 1(-1).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871102     DOI: 10.1016/0195-6701(86)90012-5

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  11 in total

1.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

2.  Determination of teicoplanin concentrations in serum by high-pressure liquid chromatography.

Authors:  B Joos; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

3.  Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.

Authors:  R N Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 5.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

6.  Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.

Authors:  C Leport; C Perronne; P Massip; P Canton; P Leclercq; E Bernard; P Lutun; J J Garaud; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

7.  Teicoplanin in the treatment of gram-positive-bacterial endocarditis.

Authors:  P Martino; M Venditti; A Micozzi; C Brandimarte; G Gentile; C Santini; P Serra
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Pharmacokinetics of teicoplanin in pediatric patients.

Authors:  A Terragna; G Ferrea; A Loy; A Danese; A Bernareggi; L Cavenaghi; R Rosina
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

9.  Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.

Authors:  M Bonati; G L Traina; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

10.  Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.

Authors:  A Del Favero; L Patoia; R Rosina; G Buniva; A Danese; A Bernareggi; E Molini; L Cavenaghi
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.